ArticleThe American journal of pathology1999
Human vascular adhesion protein-1 in smooth muscle cells.
Article in The American journal of pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 85 citations in OpenAlex.
- Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [Respiratory research · 2025Trial
- Review
- The role of VAP-1 in cardiovascular disease: a review.Frontiers in cardiovascular medicine · 2025Review
- Vascular-adhesion protein 1 in giant cell arteritis and polymyalgia rheumatica.Frontiers in medicine · 2024Review
- Increased atherosclerotic plaque in AOC3 knock-out in ApoEFrontiers in cardiovascular medicine · 2022Article
- The cellular function and molecular mechanism of formaldehyde in cardiovascular disease and heart development.Journal of cellular and molecular medicine · 2021Review
- SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases.Frontiers in pharmacology · 2021Review
- Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation.Antioxidants & redox signaling · 2019Review
- Inhibition of Semicarbazide-sensitive Amine Oxidase Reduces Atherosclerosis in Cholesterol-fed New Zealand White Rabbits.Scientific reports · 2018Article
- Smooth muscle-generated methylglyoxal impairs endothelial cell-mediated vasodilatation of cerebral microvessels in type 1 diabetic rats.British journal of pharmacology · 2016Article
- Article
- How Escherichia coli tolerates profuse hydrogen peroxide formation by a catabolic pathway.Journal of bacteriology · 2013Article
- Arterial vascular cell line expressing SSAO: a new tool to study the pathophysiology of vascular amine oxidases.Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- Article
- Reaction of vascular adhesion protein-1 (VAP-1) with primary amines: mechanistic insights from isotope effects and quantitative structure-activity relationships.The Journal of biological chemistry · 2011Article
- Localization of vascular adhesion protein-1 (VAP-1) in the human eye.Experimental eye research · 2010Article
- Copper nanoparticle cues for biomimetic cellular assembly of crosslinked elastin fibers.Acta biomaterialia · 2009Article
- Semicarbazide-sensitive amine oxidase in annulo-aortic ectasia disease: relation to elastic lamellae-associated proteins.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2004Article
- Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes.The Biochemical journal · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human vascular adhesion protein-1 (VAP-1) is a dual-function molecule with adhesive and enzymatic properties. In addition to synthesis in endothelial cells, where it mediates lymphocyte binding, VAP-1 is expressed in smooth muscle cells. Here we studied the expression, biochemical structure, and function of VAP-1 in muscle cells and compared it to those in endothelial cells. VAP-1 is expressed on the plasma membrane of all types of smooth muscle cells, but it is completely absent from cardiac and skeletal muscle cells. In tumors, VAP-1 is retained on all leiomyoma cells, whereas it is lost in half of leiomyosarcoma samples. In smooth muscle VAP-1 predominantly exists as a approximately 165-kd homodimeric glycoprotein, but a trimeric (approximately 250 kd) form of VAP-1 is also found. It contains N-linked oligosaccharide side chains and abundant sialic acid decorations. In comparison, in endothelial cells dimeric VAP-1 is larger, no trimeric forms are found, and VAP-1 does not have N-glycanase-sensitive oligosaccharides. Unlike endothelial VAP-1, VAP-1 localized on smooth muscle cells does not support binding of lymphocytes. Instead, it deaminates exogenous and endogenous primary amines. In conclusion, VAP-1 in smooth muscle cells is structurally and functionally distinct from VAP-1 present on endothelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.